A Phase 3 interventional study of Nanocrystalline Megestrol Acetate and Standard Antitumor Therapy in Cachexia and Hepatocellular Carcinoma, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Megestrol Acetate in Cachexia — 3 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Cachexia.
Among the 15 studies testing Megestrol Acetate in Cachexia, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 14th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →3 of the 15 studies testing Megestrol Acetate in Cachexia are open now, in 1 country. Recruiting first, the newest first:
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–85
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 68 is close to the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 48 across the 12 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 4 studies filed under Cachexia — fewer than ten, so there is no comparison to draw.
3 of the studies testing Megestrol Acetate in Cachexia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356037Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | 2027-06-30 |
| NCT07243379Changchun GeneScience Pharmaceutical Co., Ltd.A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia | 2026-12-31 |
| NCT07565415Nanfang Hospital, Southern Medical UniversityNanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing Megestrol Acetate in Cachexia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, randomized, parallel-controlled clinical trial. The primary objective is to evaluate the superiority and safety of nanocrystalline megestrol acetate in combination with standard therapy compared with standard therapy alone in improving appetite and body mass index (BMI) during treatment in patients with early-stage or locally advanced hepatocellular carcinoma at the cachexia stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nanocrystalline Megestrol Acetate Oral Suspension + Standard Antitumor Therapy
Drug: Nanocrystalline Megestrol Acetate · Combination Product: Standard Antitumor Therapy
Standard Antitumor Therapy
Combination Product: Standard Antitumor Therapy
Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.
Standard Antitumor Therapy
The proportion of subjects with improved appetite based on A/CS-12 assessment.
Time frame: The proportion of subjects with improved appetite based on A/CS-12 assessment in 12 weeks
Proportion of patients with BMI increase
Time frame: Proportion of patients with BMI increase in 12 weeks
Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd. →